Sorrento Therapeutics Mexico Wins Tender to Sell COVISTIX Tests to Mexico City Government
January 13, 2022 10:14 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today Sorrento Therapeutics Mexico (“Sorrento Mexico”), a Sorrento company, has won the...
Sorrento Therapeutics Announces the Unexpected Death of its Chief Financial Officer
January 07, 2022 17:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the unexpected passing of Mr. Najjam Asghar, Chief Financial Officer and Senior...
Dr. Henry Ji to Present at HC Wainwright BIOCONNECT Virtual Conference (January 10th – 13th)
January 07, 2022 11:20 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Dr. Henry Ji to Participate in Longwood Healthcare Leaders Winter Webconference Panel on January 6th 2022
January 04, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Sorrento Announces COVISTIX COVID-19 Virus Rapid Antigen Detection Test Detects the Omicron Variant
December 27, 2021 09:20 ET
|
Sorrento Therapeutics, Inc.
COVISTIX maintains its ability to detect the Omicron Variant, in addition to detecting SARS-CoV-2 and all of its major variants of concern (VoCs);COVISTIX has the potential to be a “Best-in-Class”...
Sorrento Therapeutics Mexico Executes Second Contract for Sale of 10 Million COVISTIX Tests for Mexico Market
December 27, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO and MEXICO CITY, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico (“Sorrento Mexico”),...
Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors
December 20, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed...
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
December 09, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA™) Pivotal...
Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
December 07, 2021 13:42 ET
|
Sorrento Therapeutics, Inc.
A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients.The injections were well tolerated and both patients were discharged home after a brief period of...
Sorrento Therapeutics’ Clinical Laboratory Receives Accreditation From the College of American Pathologists
December 07, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the Accreditation Committee of the College of American Pathologists (CAP) has...